Phase III study shows erenumab significantly reduces monthly migraine days
Swiss pharma giant Novartis (NOVN: VX) has released positive top-line results from ARISE, the first Phase III study evaluating the efficacy and safety of monthly subcutaneous AMG 334 (erenumab) 70mg in episodic migraine prevention.
The study met the primary endpoint, demonstrating a statistically-significant reduction from baseline in monthly migraine days in patients treated with AMG 334 compared with placebo at 12 weeks. AMG 334 is specifically designed to prevent migraine by blocking the calcitonin gene-related peptide (CGRP) receptor that is believed to have a critical role in mediating the incapacitating pain of migraine.
AMG 334 is being co-developed by US biotech major Amgen (Nasdaq: AMGN) and Novartis. As part of the collaboration, Amgen retained commercialization rights in the USA, Canada and Japan, while Novartis has rights in Europe and the rest of the world.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze